Pfizer and BioNTech mentioned on Thursday that their vaccine to stop flu and COVID-19 generated a powerful immune response towards strains of the viruses in an early- to mid-stage trial. (Johanna Geron, Reuters)
Estimated learn time: Lower than a minute
NEW YORK — Pfizer and German companion BioNTech mentioned on Thursday that their vaccine to stop flu and COVID-19 generated a powerful immune response towards strains of the viruses in an early- to mid-stage trial.
The businesses mentioned they plan to begin a late-stage trial within the coming months.
“This vaccine has the potential to reduce the influence of two respiratory ailments with a single injection and should simplify immunization practices,” Annaliesa Anderson, Pfizer’s head of vaccine analysis and growth, mentioned in an announcement.
Within the trial, the vaccine candidates had been in comparison with a licensed influenza vaccine and the businesses’ up to date COVID-19 vaccine given on the identical go to.
The information from the trial confirmed that the flu-COVID vaccine demonstrated sturdy immune responses to influenza A, influenza B and SARS-CoV-2 strains, the businesses mentioned.
Associated tales
Most up-to-date Coronavirus tales
Extra tales chances are you’ll be fascinated with
Discover more from PressNewsAgency
Subscribe to get the latest posts sent to your email.